Iron-driven cell death may be quietly undermining heart and vascular health across a far wider spectrum of conditions than previously appreciated — and existing compounds already show promise in blocking it. For adults focused on cardiovascular longevity, the emerging science of ferroptosis reframes how oxidative damage and iron dysregulation intersect in the arterial wall, heart muscle, and valvular tissue.
Ferroptosis is a genetically regulated, iron-dependent form of cell death distinct from apoptosis and necrosis, driven by the lethal accumulation of lipid peroxides when antioxidant defenses — particularly the glutathione peroxidase 4 (GPX4) axis — are overwhelmed. This comprehensive review in Redox Biology maps ferroptotic mechanisms across eight cardiovascular disease contexts: atherosclerosis, aortic aneurysm, aortic dissection, vascular aging, calcific aortic valve disease, myocardial ischemia-reperfusion injury, cardiomyopathy, and heart failure. Key regulatory nodes identified include the system Xc- cystine-glutamate transporter, transferrin receptor-mediated iron uptake, and ferritin autophagy (ferritinophagy). Among pharmacological agents reviewed, iron chelators deferoxamine and deferiprone, the antioxidants vitamin E, alpha-lipoic acid, and selenium, plus the synthetic ferroptosis inhibitor Ferrostatin-1 all demonstrated cardiovascular protection in animal models.
The significance here extends beyond any single drug. Ferroptosis research is moving rapidly from oncology — where it was first characterized — into cardiometabolic medicine, and this review signals that the cardiovascular field is approaching a translational inflection point. The breadth of conditions implicated suggests ferroptosis may be a common pathological thread rather than a disease-specific curiosity. However, critical caveats apply: virtually all cited pharmacological evidence derives from animal or cell-culture studies, and no ferroptosis-targeting agent has yet demonstrated cardiovascular efficacy in a human randomized trial. The mechanistic complexity — ferroptosis regulation intersects with mitochondrial function, NRF2 signaling, and lipid metabolism — also means therapeutic targeting carries significant off-target risk. This review is best classified as a high-quality synthesis of a genuinely emerging paradigm, incremental in itself but pointing toward what could be a paradigm-shifting therapeutic target class within five to ten years.
